Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Express Scripts
McKesson
AstraZeneca
Dow

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Sotagliflozin

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Sotagliflozin?

Sotagliflozin is an investigational drug.

There have been 33 clinical trials for Sotagliflozin. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2019.

The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Diabetes Mellitus, Type 1. The leading clinical trial sponsors are Sanofi, Lexicon Pharmaceuticals, and The University of Texas Health Science Center at San Antonio.

There are thirteen US patents protecting this investigational drug and one hundred and seventy-six international patents.

Recent Clinical Trials for Sotagliflozin
TitleSponsorPhase
Dapagliflozin Plus Pioglitazone in T1DMThe University of Texas Health Science Center at San AntonioPhase 4
Sotagliflozin Multiple-dose Phase I Study in Healthy Chinese SubjectsSanofiPhase 1
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without SulfonylureaSanofiPhase 3

See all Sotagliflozin clinical trials

Clinical Trial Summary for Sotagliflozin

Top disease conditions for Sotagliflozin
Top clinical trial sponsors for Sotagliflozin

See all Sotagliflozin clinical trials

US Patents for Sotagliflozin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sotagliflozin   Start Trial Inhibitors of sodium glucose co-transporter 2 and methods of their use Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)   Start Trial
Sotagliflozin   Start Trial Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)   Start Trial
Sotagliflozin   Start Trial Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)   Start Trial
Sotagliflozin   Start Trial Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetr- ahydro-2H-pyran-3,4,5-triol and methods of their use Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)   Start Trial
Sotagliflozin   Start Trial Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)   Start Trial
Sotagliflozin   Start Trial Sulfanyl-tetrahydropyran-based compounds and methods of their use Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sotagliflozin

Drugname Country Document Number Estimated Expiration Related US Patent
Sotagliflozin Argentina 063047 2026-09-29   Start Trial
Sotagliflozin Austria 496888 2026-09-29   Start Trial
Sotagliflozin Australia 2007304971 2026-09-29   Start Trial
Sotagliflozin Brazil PI0717156 2026-09-29   Start Trial
Sotagliflozin Canada 2664688 2026-09-29   Start Trial
Sotagliflozin China 101343296 2026-09-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
AstraZeneca
Baxter
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.